- Home
- TEL vs ARGX Comparison
TEL vs ARGX Comparison
Compare TEL & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEL
- ARGX
- Stock Information
- Founded
- TEL 1941
- ARGX 2008
- Country
- TEL Ireland
- ARGX Netherlands
- Employees
- TEL N/A
- ARGX N/A
- Industry
- TEL Industrial Machinery/Components
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TEL Technology
- ARGX Health Care
- Exchange
- TEL Nasdaq
- ARGX Nasdaq
- Market Cap
- TEL 43.5B
- ARGX 37.3B
- IPO Year
- TEL 2007
- ARGX 2017
- Fundamental
- Price
- TEL $140.92
- ARGX $656.26
- Analyst Decision
- TEL Buy
- ARGX Strong Buy
- Analyst Count
- TEL 11
- ARGX 20
- Target Price
- TEL $159.36
- ARGX $640.33
- AVG Volume (30 Days)
- TEL 1.5M
- ARGX 228.4K
- Earning Date
- TEL 01-22-2025
- ARGX 02-27-2025
- Dividend Yield
- TEL 1.84%
- ARGX N/A
- EPS Growth
- TEL 71.45
- ARGX N/A
- EPS
- TEL 10.34
- ARGX N/A
- Revenue
- TEL $15,845,000,000.00
- ARGX $1,908,659,000.00
- Revenue This Year
- TEL $5.31
- ARGX $61.99
- Revenue Next Year
- TEL $6.72
- ARGX $42.48
- P/E Ratio
- TEL $13.63
- ARGX N/A
- Revenue Growth
- TEL N/A
- ARGX 85.56
- 52 Week Low
- TEL $128.52
- ARGX $349.86
- 52 Week High
- TEL $159.98
- ARGX $663.78
- Technical
- Relative Strength Index (RSI)
- TEL 35.41
- ARGX 69.22
- Support Level
- TEL $139.80
- ARGX $613.00
- Resistance Level
- TEL $146.45
- ARGX $637.08
- Average True Range (ATR)
- TEL 2.93
- ARGX 13.38
- MACD
- TEL -0.15
- ARGX 1.90
- Stochastic Oscillator
- TEL 11.73
- ARGX 85.19
About TEL TE Connectivity Ltd. New Switzerland Registered Shares
TE Connectivity is the largest electrical connector supplier in the world, supplying interconnect and sensor solutions to the transportation, industrial, and communications markets. With operations in 150 countries and over 500,000 stock-keeping units, TE has a broad portfolio that forms the electrical architecture of its end customers' cutting-edge innovations.
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.